Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Response Biomedical and BioTheranostics

Premium

Response Biomedical said this week that its board of directors has appointed Jeffrey Purvin to be CEO and a director, and that Peter Thompson has stepped down from the interim CEO position that he has held for nearly one year. Thompson will remain executive chairman of the company's board of directors.

Purvin has 30 years of experience marketing consumer and medical products and is a member of the board of directors, audit committee, and finance committee and chair of the compensation committee at Cardica.


BioTheranostics said this week that it has added Brad Smith, Brian Armstrong, and Francois Valencony to its board of directors, and has hired Mary Jo Mullen and Isaac Bright to its senior management, naming Mullen chief commercial officer and Bright vice president of corporate development.

Smith is a former vice chairman of Laboratory Corporation of America; Armstrong is chief financial officer for BioMérieux; and Valencony is managing director of Merieux Development.

Mullen formerly held senior sales management positions at LabCorp. Bright joins the company from QuantaLife and held corporate and business development leadership posts at Medtronic and an investment banking position at CIBC World Markets.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.